Anticoagulation Combined With Tocilizumab for Interleukin-6 Receptor Inhibition in Acute Cerebral Venous Thrombosis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This study aims to evaluate the efficacy and safety of tocilizumab, an interleukin-6 (IL-6) receptor antagonist, combined with standard anticoagulant therapy compared with standard anticoagulant therapy alone in patients with acute cerebral venous thrombosis (CVT).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Aged 18-80 years.
• Acute cerebral venous thrombosis (CVT) confirmed by neuroimaging, including MRI, MRV, CTV, MRBTI, or DSA.
• Time from symptom onset to enrollment within 14 ± 14 days.
• Written informed consent obtained from the participant.
• Ability and willingness to comply with the study protocol and scheduled follow-up visits.
Locations
Other Locations
China
Xuanwu Hospital
RECRUITING
Beijing
Contact Information
Primary
Xunming Ji
jixm@ccmu.edu.cn
01083198962
Backup
Chen Zhou
chenzhou2013abc@163.com
Time Frame
Start Date: 2025-03-01
Estimated Completion Date: 2028-09-30
Participants
Target number of participants: 80
Treatments
Experimental: Tocilizumab
Participants will receive guideline-recommended standard treatment plus a single intravenous infusion of tocilizumab.
Placebo_comparator: Standard treatment
Participants will receive guideline-recommended standard treatment plus a single intravenous infusion of placebo.
Related Therapeutic Areas
Sponsors
Leads: Capital Medical University